SCHEMBL23783191

SCHEMBL23783191

N#Cc1c(Cl)nc2c(c1C(F)(F)F)CCCC2

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.66
NSD2 O96028 1/20 0.66
MAPT P10636 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
KDM4E B2RXH2 9/20 0.47
HTT P42858 4/20 0.44
GLA P06280 1/20 0.44
ALDH1A1 P00352 6/20 0.44
HSD17B10 Q99714 6/20 0.44
HPGD P15428 4/20 0.44
KMT2A Q03164 2/20 0.44
NPSR1 Q6W5P4 2/20 0.44
GAA P10253 1/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 3/20 0.40
MEN1 O00255 1/20 0.39
ADORA2A P29274 1/20 0.38
USP2 O75604 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30501086 1.00 MAPK1 (0.66) MAPK1NSD2MAPTTDP1KDM4E
SCHEMBL14034145 0.81 TDP1 (0.54) MAPK1NSD2MAPTTDP1KDM4E
SCHEMBL30774262 0.78 NSD2 (0.77) MAPK1NSD2KDM4EHTTGLA
SCHEMBL24373873 0.78 NSD2 (0.77) MAPK1NSD2KDM4EHTTGLA
SCHEMBL27096572 0.77 NSD2 (0.74) MAPK1NSD2KDM4EHTTGLA
SCHEMBL31647552 0.76 NSD2 (0.72) MAPK1NSD2KDM4EHTTGLA
SCHEMBL23783069 0.76 NSD2 (0.72) MAPK1NSD2KDM4EHTTGLA
SCHEMBL23782775 0.75 NSD2 (0.66) MAPK1NSD2KDM4EHTTGLA
SCHEMBL24373875 0.75 NSD2 (0.71) MAPK1NSD2KDM4EHTTGLA
SCHEMBL22312045 0.72 NSD2 (0.67) MAPK1NSD2MAPTKDM4EHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. 2023-05-11 US disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 WO disclosed
WO-2021178780-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS ESCAPE Bio, Inc. (US) 2021-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230148214-A1 INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS LRRK2, PARK7, GDI2 MAPK1 650/4885NSD2 1225/4885MAPT 66/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.